-
evidence for efficacy (i.e. the target gene is linked to a variant significantly associated with the drug indication, cf Illustration) are twice as likely to succeed in a clinical trial. However, challenges
-
to viruses i.e., HIV-1, Hepatitis E and B, as well as emerging viruses such as SARS-CoV-2. These recombinant antibodies represent unique “fingerprints” for each B-cell clone, and when characterized at both
Enter an email to receive alerts for "I.E" positions in France